Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 15, 2018

Addition of the PARP Inhibitor Veliparib Plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Addition of the PARP Inhibitor Veliparib Plus Carboplatin or Carboplatin Alone to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer (BrighTNess): A Randomised, Phase 3 Trial
Lancet Oncol 2018 Feb 28;[EPub Ahead of Print], S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, J Huober, M Golshan, G von Minckwitz, D Maag, D Sullivan, N Wolmark, K McIntyre, JJ Ponce Lorenzo, O Metzger Filho, P Rastogi, WF Symmans, X Liu, CE Geyer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading